Skip to main content

ARF1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human ARF1 knockout HeLa cell line (AB264939), expandable thumbnail
  • Western blot - Human ARF1 knockout HeLa cell line (AB264939), expandable thumbnail
  • Sanger Sequencing - Human ARF1 knockout HeLa cell line (AB264939), expandable thumbnail
  • Sanger Sequencing - Human ARF1 knockout HeLa cell line (AB264939), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Alternative names

Recommended products

ARF1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
ARF1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255448). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

ARF1 also known as ADP-ribosylation factor 1 or ARF1 protein is a small GTPase with a molecular mass of approximately 20 kDa. Commonly expressed in a variety of cell types ARF1 plays a central role in vesicle trafficking. As an activator ARF1 interacts with different GTPase-activating proteins such as ARFGAP1 and BIG1 ensuring the proper distribution of proteins and lipids in cells. ARF1's expression occurs across numerous cellular compartments including the Golgi apparatus aiding in the formation of transport vesicles.

Biological function summary

ARF1 is essential in regulating membrane dynamics and vesicular traffic. It forms part of the COPI and clathrin-coated vesicle complexes where it recruits coat proteins to budding vesicles. This recruitment is fundamental for maintaining Golgi structure and function. Additionally ARF1 plays a role in cytokinesis by interacting with the septin cytoskeleton. The protein also influences actin cytoskeleton remodeling which is pivotal for cell shape changes and motility.

Pathways

ARF1 is central to both the endocytic and secretory pathways. It collaborates with proteins like ARFS and 3F1 in modulating the trafficking of cargo between the endoplasmic reticulum and Golgi. Within the secretory pathway ARF1 interacts with SNARE proteins to facilitate vesicle docking and fusion. Its actions in pathways maintain cellular homeostasis and promote proper cellular response to various stimuli.

Associated diseases and disorders

ARF1 has links to cancer and Alzheimer's disease. Overexpression of ARF1 correlates with tumor progression and metastasis impacting cell proliferation and survival mechanisms. Additionally its disruption associates with Alzheimer's where it may influence amyloid precursor protein processing alongside interactions with GAP proteins. Understanding ARF1's role in these conditions highlights its potential as a therapeutic target stressing the importance of studying its interactions with disease-related proteins.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com